TY - JOUR AU - Sean H. Lim, AU - Stephen A. Beers, AU - Ruth R. French, AU - Peter W.M. Johnson, AU - Martin J. Glennie, AU - Mark S. Cragg, PY - 2010/01/11 Y2 - 2024/03/28 TI - Anti-CD20 monoclonal antibodies: historical and future perspectives JF - Haematologica JA - haematol VL - 95 IS - 1 SE - Review Articles DO - 10.3324/haematol.2008.001628 UR - https://haematologica.org/article/view/5459 SP - 135-143 AB - Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced. ER -